top of page

Differentiated Antibodies
Multispecifics Design

Trican Biotechnology focuses on the construct and development of innovative therapeutic modalities that address unmet medical needs.

Home

History

Trican Biotechnology, founded in 2015, is designing antibodies based on in vitro and in silico tools for in vivo validation. Through open technology integration with our proprietary platform, Trican delivers differentiated antibodies to address disease setting across oncology, immunology, and ophthalmology.  

We are actively partnering globally with antibody-drug conjugates (ADCs), drug delivery, and bispecific/multispecific innovators.
 

Fully-Human IgG theopoetical antibody discovery

Vision

Innovation, Integrity, Compassion

Guided by the beliefs for innovation, integrity, and compassion for all humanity, Trican Biotechnology strives to continuously advance our antibody engineering platform for speed and quality. We are singularly focused on driving forward novel antibody-based innovations to clinical studies. No one company can do everything.  Thus, we aim to create candidates in collaboration that address unmet medical needs, improve the quality of life for patients, and create value for all stakeholders in the innovation ecosystem. 

SERAbody Platform

Briefly, Trican Biotechnology harvested and assembled tumor reactive B cell receptors sequences into our proprietary DART library ''Directed and Activated immune Response against Tumors/lesions''. 
Next-gen sequencing revealed more than 200 billion binders from DART with fully-human immunogenetics after recombination. For discovery campaigns Trican applies our proprietary high-throughput selection SERA ''Serially Enriched Recombinant Antibodies'' methodology. 

 

Binders or SERAbodies from DART library by Trican are selected based on diversity, specificity, developability, and finally affinity against targets of interest. Trican engineers can further format and characterize SERAbodies into IgG or multispecifics candidates with targeted functionalities for further clinical development.  

Multiple patents have been granted based on SERAbodies raised by Trican.

DART

DART
''Directed Activated  immune Response against Tumors/lesions''  B-Cell Receptor Library

DART_font
SERA

SERA
''Serially Enriched Recombinant Antibodies'' High-Throughput Selection platform

SERA_font
IgG antibody discovery

Trican's Antibody Discovery Mapping 

SERAbody Portfolio

ID

Construct

Indication

Status

TRB007

bispecific

Ophthalmology

Optioned

TRB817

bispecific

Ophthalmology

Characterization

TRB303

IgG

Oncology

Partnered

TRB824

Bispecific

Oncology

In development

TRB301

IgG

Nephrology

Ready

Contact

Head Office

24F-7 No.99 Section1, Xintaiwu Road,

Xizhi District, New Taipei City, 221

Tel: +886-2-2697-2685

Fax: +886-2-2697-2015

info@tricanbiotech.com

Inquiries

For any inquiries, questions or commendations, please call: +886-2-2697-2685 or fill out the following form

Employment

To apply for a job with Trican Biotech,

please see detailed information on the 104 website: www.104.com.tw

Success! Message received.

+886-2-2697-2685

24F-7 No.99 Section1, Xintaiwu Road, Xizhi District, New Taipei City, Taiwan

Copyright © 2024 Trican Biotehcnology Inc

bottom of page